Gene Fusion Testing Market, By Indication (Hematological Malignancies, Solid Tumors), By Technology (FISH, NGS, PCR, IHC), By End-Users (Hospitals, Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Academic & Research Centers), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2032

[PDF] Gene Fusion is defined as joining of two genes which are transcribed and translated as a single unit. Gene fusion testing are used in cancer diseases, whereas the advancement in NGS (next generation sequencing) have revolutionized the estimation and characterization of fusion genes in oncology.

Gene Fusion Testing Market Size:

Growing Prevalence of Cancer Diseases to fuel market growth

Growing prevalence of cancer diseases has become major driving factor in market growth. Rapid growth in urbanization coupled with adoption of unhealthy lifestyle and poor nutrition food has given positive impact on Gene Fusion Testing Market growth. Rising cancer diseases led to rise in demand for advanced diagnostic techniques to effective treatment which in turn, facilitate the demand for Gene Fusion Testing market growth. The gene fusion testing is a molecular diagnostic method used for identifying and analyzing the distinct genetic alterations in cancer cells which is likely to propel market growth.

For instance, according to CDC (Centers for Disease Control and Prevention) in 2019, around 1,752,735 new cancer cases were reported and 599,589 people were died of cancer disease in United States of America.

Restrains:

The high complexity of testing process has restrained market growth. Further, lack of standardization and reimbursement barriers have hampered the demand for Gene Fusion Testing Market growth.

Gene Fusion Testing Market is segmented based on Indication, Technology, End-Users and Region.

Indication Insight

On the basis of Indication, Gene Fusion Testing Market is segmented into Hematological Malignancies, Solid Tumors.

Technology Insight

On the basis of Technology, Gene Fusion Testing Market is segmented into FISH (Fluorescence in Situ Hybridization), NGS (Next-Generation Sequencing), PCR (Polymerase Chain Reaction), IHC (Immunohistochemistry).

End-Users Insights

On the basis of End-Users, Gene Fusion Testing Market is segmented into Hospitals, Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Academic & Research Centers.

Gene Fusion Testing Market Regional Insights:

On region the Gene Fusion Testing Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

North America market is estimated to witness a significantly high revenue share over the forecast period due to rising prevalence of cancer diseases, continuous technological development, presence of major players and advancement in diagnostic testing.

Recent Development:

The New Launched Product News,

• In January 2023, Arima Genomics announced an agreement with Protean BioDiagnostics to develop NGS-based (next generation sequencing) gene fusion testing service. The new gene fusion testing service by using Arima’s novel genomic technology will help in identifying the clinically actionable gene fusions in patients with tumor tissues.
• In March 2021, Biocartis launched new rapid lab workflow solution ‘Idylla GeneFusion Assay’ for gene fusion testing. The new launched assay help in detecting various gene fusions that are relevant in cancer research in a single cartridge.

Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2022 to 2032.

Few Other Promising Reports:

• Cancer Diagnostics Market
• Cancer Therapeutics and Biotherapeutics Market
• Oncology Molecular Diagnostics Market

The key players operating the Gene Fusion Testing Market includes, Amoy Diagnostics Co. Ltd., Arima Genomics, F. Hoffman-La Roche Ltd., ArcherDX, Biocartis, Illumina, Danaher Corporation, Guardant Health, Biocare Medical LLC., and Myriad Genetics Inc.

• Amoy Diagnostics Co. Ltd.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• Arima Genomics
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• F. Hoffman-La Roche Ltd.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• ArcherDX
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Biocartis
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Illumina
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Danaher Corporation
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Guardant Health
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Biocare Medical LLC.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Myriad Genetics Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

1. The Last Word
   • Future Impact
   • About Us
   • Contact